Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1170918 | 1.00 | TP53 (0.38) | TP53THRBMAPTHTTSMN1; SMN2 | |
| SCHEMBL13319976 | 0.90 | TP53 (0.51) | TP53THRBMAPTHTTSMN1; SMN2 | |
| SCHEMBL12879901 | 0.90 | TP53 (0.51) | TP53THRBMAPTHTTSMN1; SMN2 | |
| SCHEMBL12864975 | 0.90 | TP53 (0.51) | TP53THRBMAPTHTTSMN1; SMN2 | |
| SCHEMBL12880191 | 0.89 | TP53 (0.38) | TP53THRBMAPTHTTSMN1; SMN2 | |
| SCHEMBL12864536 | 0.87 | TP53 (0.36) | TP53THRBMAPTHTTSMN1; SMN2 | |
| SCHEMBL12864537 | 0.85 | TP53 (0.33) | TP53THRBMAPTHTTSMN1; SMN2 | |
| SCHEMBL1170999 | 0.83 | MAPT (0.39) | TP53THRBMAPTHTTSMN1; SMN2 | |
| SCHEMBL13319973 | 0.83 | MAPT (0.39) | TP53THRBMAPTHTTSMN1; SMN2 | |
| SCHEMBL12903503 | 0.83 | TP53 (0.36) | TP53THRBMAPTHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, AOC1 | TP53 2774/4885THRB 1558/4885MAPT 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.